LCN2 and inflammatory bowel disease: Butyrate administration in human studies showed significant reduction in release of neutrophil-mediated proinflammatory cytokines and suppression of IBD biomarkers such as calprotectin (CP) and LCN2 (lipocalin 2) [98].